Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant DDI Study with Rosuvastatin
NCT04889287Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elinzanetant in vasomotor symptoms, sponsored by Bayer. Primary endpoints: Maximum plasma concentration of rosuvastatin and Area under the concentration versus time curve of rosuvastatin. Started May 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04889287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889287.